Orthocell revenue jumps 44% as US growth builds

Orthocell Ltd CEO and managing director Paul Anderson talked with Proactive about the company’s record quarterly and full-year revenue, accelerating adoption of its Remplir™ nerve repair device and the outlook for further commercial growth in Australia, the United States and other international markets. Orthocell reported revenue of A$3.8 million for the June quarter, representing a 20% increase from the March quarter and a 36% rise compared with the corresponding period last year. FY2026 revenue increased by 44% to a record A$13.2 million, supported by growing sales of Remplir and Striate+™ across domestic and international markets. Anderson said product revenue was being generated across Australia and a growing number of international markets, including Thailand, Hong Kong, Singapore, Canada and the United States. He added that the company had yet to see the full contribution from its US commercial rollout, describing the result as “great numbers with a whole heap of upside”. The interview also covered Orthocell’s expanding US team, growing hospital access, increasing surgeon adoption and stronger distributor interest. With A$44 million in cash, Orthocell plans to continue investing in commercial expansion, manufacturing capability and its pathway towards cash flow break-even. Anderson said investors could expect a material increase in revenue as more surgeons, hospitals and distributors adopt the company’s products. Visit Proactive’s YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications for future content.